Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 1-5 Year Investment Grade Corporate Bond ETF
IGSB
|
+$596M |
| 2 |
Vanguard Intermediate-Term Treasury ETF
VGIT
|
+$429M |
| 3 |
Verizon
VZ
|
+$399M |
| 4 |
Amgen
AMGN
|
+$214M |
| 5 |
Citizens Financial Group
CFG
|
+$212M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MBS ETF
MBB
|
+$561M |
| 2 |
iShares National Muni Bond ETF
MUB
|
+$535M |
| 3 |
Oracle
ORCL
|
+$144M |
| 4 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$143M |
| 5 |
Vanguard Mortgage-Backed Securities ETF
VMBS
|
+$141M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.17% |
| 2 | Financials | 13.07% |
| 3 | Healthcare | 12.05% |
| 4 | Consumer Discretionary | 10.98% |
| 5 | Industrials | 9.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2326
Teva Pharmaceuticals
TEVA
$40.8B
| $5.25M | ﹤0.01% |
530,797
| – | – |
|
2327
Rhythm Pharmaceuticals
RYTM
$6.81B
| $5.24M | ﹤0.01% |
267,631
+15,409
| +6% | +$320K |
|
2328
Telos
TLS
$332M
| $5.24M | ﹤0.01% |
154,007
+42,931
| +39% | +$1.45M |
|
|
NFBK
2329
DELISTED
Northfield Bancorp
NFBK
| $5.23M | ﹤0.01% |
318,614
-1,409
| -0.4% | -$23.2K |
|
|
GBIO
2330
DELISTED
Generation Bio
GBIO
| $5.22M | ﹤0.01% |
19,389
+1,156
| +6% | +$346K |
|
|
AEVA
2331
Aeva Technologies
AEVA
$1.2B
| $5.21M | ﹤0.01% |
+98,648
| New | +$4.98M |
|
|
CCF
2332
DELISTED
Chase Corporation
CCF
| $5.21M | ﹤0.01% |
50,747
+870
| +2% | +$96.2K |
|
2333
RE/MAX Holdings
RMAX
$193M
| $5.2M | ﹤0.01% |
155,940
+29,125
| +23% | +$1.05M |
|
2334
Personalis
PSNL
$1.35B
| $5.2M | ﹤0.01% |
205,373
+20,624
| +11% | +$472K |
|
|
NWLI
2335
DELISTED
National Western Life Group, Inc. Class A
NWLI
| $5.19M | ﹤0.01% |
23,131
+196
| +0.9% | +$46.7K |
|
2336
Theravance Biopharma
TBPH
$874M
| $5.18M | ﹤0.01% |
356,544
+23,060
| +7% | +$433K |
|
2337
BrightView Holdings
BV
$1.22B
| $5.17M | ﹤0.01% |
320,887
+49,600
| +18% | +$871K |
|
|
BTRS
2338
DELISTED
BTRS Holdings Inc. Class 1 Common Stock
BTRS
| $5.15M | ﹤0.01% |
408,380
+127,844
| +46% | +$1.85M |
|
|
WSR
2339
DELISTED
Whitestone REIT
WSR
| $5.15M | ﹤0.01% |
624,337
+136,213
| +28% | +$1.22M |
|
|
SUMO
2340
DELISTED
Sumo Logic, Inc. Common Stock
SUMO
| $5.15M | ﹤0.01% |
249,416
+146,812
| +143% | +$2.84M |
|
|
ATCO
2341
DELISTED
Atlas Corp.
ATCO
| $5.15M | ﹤0.01% |
361,126
-34,693
| -9% | -$481K |
|
|
VBIV
2342
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $5.14M | ﹤0.01% |
51,187
+1,529
| +3% | +$149K |
|
2343
Bionano Genomics
BNGO
$12.3M
| $5.14M | ﹤0.01% |
1,168
+1,057
| +952% | +$4.17M |
|
|
SRDX
2344
DELISTED
Surmodics
SRDX
| $5.13M | ﹤0.01% |
94,645
+1,664
| +2% | +$91.3K |
|
2345
Titan Machinery
TITN
$396M
| $5.11M | ﹤0.01% |
165,179
+14,331
| +10% | +$401K |
|
2346
Amphastar Pharmaceuticals
AMPH
$879M
| $5.11M | ﹤0.01% |
253,387
+5,488
| +2% | +$103K |
|
|
TVRD
2347
Tvardi Therapeutics
TVRD
$19.7M
| $5.08M | ﹤0.01% |
9,895
+335
| +4% | +$212K |
|
|
CHUY
2348
DELISTED
Chuy's Holdings, Inc. Common Stock
CHUY
| $5.08M | ﹤0.01% |
136,359
+2,176
| +2% | +$92.6K |
|
2349
ALX Oncology
ALXO
$261M
| $5.07M | ﹤0.01% |
92,704
+1,734
| +2% | +$104K |
|
|
AERI
2350
DELISTED
Aerie Pharmaceuticals
AERI
| $5.05M | ﹤0.01% |
315,652
+16,851
| +6% | +$289K |
|
Similar funds
Charles Schwab's Q2 2021 Portfolio in Review
As of Q2 2021, Charles Schwab held 3,648 positions worth $301B, up 10% from $273B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Charles Schwab's Q2 2021 filing shows 163 new, 2,481 increased, 676 reduced and 240 closed positions. Its largest new stake was Vanguard Intermediate-Term Treasury ETF: 6,338,757 shares worth $430M. The largest sale was iShares MBS ETF, an estimated $561M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q2 2021 buy was Vanguard Intermediate-Term Treasury ETF: 6,338,757 shares worth $430M.
- Charles Schwab added most to iShares 1-5 Year Investment Grade Corporate Bond ETF in Q2 2021, an estimated $596M increase.
- Charles Schwab's biggest Q2 2021 reduction was iShares MBS ETF, cutting an estimated $561M.
- Charles Schwab fully exited Invesco S&P 500 Low Volatility ETF in Q2 2021, selling an estimated $92.7M.
- Charles Schwab's ten largest holdings make up 17% of its $301B portfolio in Q2 2021.
- Charles Schwab opened 163 new positions and closed 240 in Q2 2021.
- Charles Schwab's portfolio value rose 10% quarter-over-quarter to $301B.
Based on Charles Schwab's 13F filing for Q2 2021, filed 16 Aug 2021.